All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The ALL Hub spoke with Wendy Stock, The University of Chicago, Chicago, US. We asked, How to optimize dosing regimens for recombinant asparaginase in acute lymphoblastic leukemia (ALL)?
How to optimize dosing regimens for recombinant asparaginase in ALL?
In this interview, Wendy Stock discusses the challenges of managing asparaginase treatment in adults with ALL. Stock highlights the effectiveness of the therapy in younger adults but notes the difficulties of optimizing asparaginase dosing and managing associated toxicities, including hepatic issues, thrombosis, and pancreatitis. Stock points out the lack of formal guidelines and underscores the need for further research, including therapeutic drug monitoring and studies on anticoagulation. Ongoing studies aim to improve understanding of the risk factors for experiencing adverse events and how to optimize treatment approaches for better patient outcomes.
Agree
100%
Disagree
0%
This educational resource is independently supported by Jazz Pharmaceuticals. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Subscribe to get the best content related to ALL delivered to your inbox